A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs AZD 5213 (Primary) ; Pregabalin
  • Indications Diabetic neuropathies
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2015 Planned number of patients changed from 60 to 46 as reported by ClinicalTrials.gov.
    • 12 Jan 2015 Planned End Date changed from 1 Jun 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top